A novel machine learning model to predict high on-treatment platelet reactivity on clopidogrel in Asian patients after percutaneous coronary intervention-Reference-Cited by-同舟云学术

A novel machine learning model to predict high on-treatment platelet reactivity on clopidogrel in Asian patients after percutaneous coronary intervention

Published:2023-10-10 Issue:1 Volume:46 Page:90-100
ISSN:2210-7703
Container-title:International Journal of Clinical Pharmacy
language:en
Short-container-title:Int J Clin Pharm

Author:

Ding Lan-Ping,Li Ping,Yang Li-Rong,Pan Mang-Mang,Zhou Min,Zhang Chi,Yan Yi-Dan,Lin Hou-Wen,Li Xiao-Ye,Gu Zhi-Chun^ORCID

Funder

Ren Ji Boost Project of National Natural Science Foundation of China

Cultivation fund of clinical research of Ren Ji Hospital

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,Toxicology,Pharmacy

Link

https://link.springer.com/content/pdf/10.1007/s11096-023-01638-1.pdf

Reference43 articles.

1. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213–60. https://doi.org/10.1093/eurheartj/ehx419.

2. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the american college of cardiology/American Heart Association task force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC guideline for the management of patients with Non-ST-elevation acute coronary Syndromes, and 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e123-155. https://doi.org/10.1161/cir.0000000000000404.

3. Wang D, Yang XH, Zhang JD, et al. Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis. BMC Cardiovasc Disord. 2018;18(1):217. https://doi.org/10.1186/s12872-018-0948-4.

4. Claassens DMF, Bergmeijer TO, Vos GJA, et al. Clopidogrel versus ticagrelor or prasugrel after primary percutaneous coronary intervention according to CYP2C19 genotype: a popular genetics subanalysis. Circ Cardiovasc Interv. 2021;14(4):e009434. https://doi.org/10.1161/circinterventions.120.009434.

5. Fan W, Plent S, Prats J, et al. Trends in P2Y12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice. Am J Cardiol. 2016;117(9):1439–43. https://doi.org/10.1016/j.amjcard.2016.02.012.